Ładuje się......
Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date
Hepatocellular carcinoma (HCC) is the fastest rising cause of cancer-related death in the United States and carries a very poor prognosis, with a median survival time of <50% at 1 year for advanced disease. To date, sorafenib is the only therapy approved by the Food and Drug Administration for th...
Zapisane w:
| Wydane w: | J Hepatocell Carcinoma |
|---|---|
| Główni autorzy: | , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Dove Medical Press
2016
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5118026/ https://ncbi.nlm.nih.gov/pubmed/27896243 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S106072 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|